As clinical trial complexity, duration, and cost continue to rise, life sciences companies are turning to data to help them ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC. Amezalpat builds ...

Jenzabar, Inc., a leading provider of technology solutions for higher education, today announced that 134 institutions selected Jenzabar solutions in 2024, marking another year of strong growth and ...

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Patient enrollment is expected to begin in the first half of 2025, subject to final protocol review by regulatory authorities ...

(Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world's first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system-the ...

LifeVantage Corporation ( NASDAQ: LFVN) Q2 2025 Earnings Conference Call February 5, 2025 4:30 PM ET Reed Anderson – Managing Director-ICR Steve Fife – President and Chief Executive Officer Carl Aure ...

KalVista Pharmaceuticals, Inc. , today announced the presentation of novel data related to long-term prophylaxis and sebetralstat at the Western Society of Allergy, Asthma & Immunology (WSAAI) 2025 ...

Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.